Cargando…
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
The therapy of different advanced-stage malignancies with monoclonal antibodies blocking programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling has had an impressive long-lasting effect in a portion of patients, but in most cases, this therapy was not successful, or a secondary resis...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486151/ https://www.ncbi.nlm.nih.gov/pubmed/28635644 http://dx.doi.org/10.3390/ijms18061331 |